Industry News
Chemomab announces poster presentation at AASLD’s The Liver Meeting 2021
New preclinical data further supports ability of CM-101 to break the vicious cycle of inflammation and fibrosis in primary sclerosing cholangitis
News & Articles
25
Selected Filters:
Industry News
Chemomab Therapeutics collaborates with Leeds University to further elucidate the role of CCL24 in vascular damage
Chemomab’s CM-101 is a first-in-class, CCL24-neutralizing monoclonal antibody expected to enter a Phase 2 clinical trial in SSc patients early next year